We retrospectively compared the long-term evolution of IgG anti-spike (S) and anti-
nucleocapsid (N) levels (Abbott immunoassays) in 116 non-severe and 115 severe SARS …

Abstract Background Most SARS-CoV-2 infected patients develop IgG antibodies within 2–3
weeks after symptom onset. Antibody levels have been shown to gradually decrease in the …

Abstract Objectives Coronavirus disease-19 (COVID-19) pandemic became the greatest
public health challenge globally. Study of dynamicity and durability of naturally developed …

Objectives Seroprevalence studies can provide a measure of SARS-CoV-2 cumulative
incidence, but a better understanding of spike and nucleocapsid (anti-N) antibody dynamics …

To the Editor—Lumley et al studied the duration and dynamics of severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) antibody responses in 452 individual healthcare …

A better understanding of the anti-SARS-CoV-2 immune response is necessary to finely
evaluate commercial serological assays but also to predict protection against reinfection and …

The comprehension of a long-term humoral immune response against SARS-CoV-2 can
shed light on the treatment and vaccination strategies of COVID-19 disease, improving the …

Kinetics of neutralizing antibodies and immunoglobulin G (IgG) against the nucleo (N) or
spike (S) proteins of severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) …

Elucidating the characteristics of human immune response against SARS-CoV-2 is of high
priority and relevant for determining vaccine strategies. We report the results of a follow-up …

Background SARS-CoV-2, the cause of coronavirus disease 2019 (COVID-19), is
associated with respiratory-related morbidity and mortality. Assays to detect virus-specific …